Yeah man! Being invested in this company since early 2011, I've seen their only product in 2011 get pulled from the market by the FDA and they were basically left out to dry and file for BK. The previous CEO bought generic drugs to supplement the losses. It's been so exciting to see the company grow from 200k in revenue to what is expected to be 2 million in revenue this quarter. By bringing in a CEO who was in a high managerial position for ACTAVIS, we are now advancing the Abuse Resistant Drugs. The market for these drugs is over 3 billion and growing very fast.
This Bio company is different from others. They have a line of profitable generics to supplement the costs of the clinical trials. I'm expecting that in a quarter or two, the generic drugs will make this company profitable including all R&D costs.
Market Data 
Markets 
AI
